NCT07606794 Supra-Iliac Anterior Quadratus Lumborum Block and Pericapsular Nerve Group (PENG) Block for Analgesia After Total Hip Arthroplasty
| NCT ID | NCT07606794 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Supra-Iliac Anterior Quadratus Lumborum Block |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-05-23 |
| Primary Completion | 2026-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-05-23 with a primary completion date of 2026-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the analgesic efficacy of supra-iliac anterior quadratus lumborum block (SA-QLB) and pericapsular nerve group (PENG) block in patients undergoing total hip arthroplasty (THA).
Eligibility Criteria
Inclusion Criteria: * Age from 18 to 75 years. * Both sexes. * American Society of Anesthesiologists (ASA) classification I-III. * Scheduled for primary elective unilateral total hip arthroplasty (THA) under spinal anesthesia. Exclusion Criteria: * Known allergies to the drugs used. * Infection at the injection site. * Bleeding disorders. * Recognized neuromuscular disorders. * Opioid addiction or dependence. * Contraindications to regional anesthesia or peripheral nerve blockade. * Body mass index (BMI) \> 40 kg/m². * Associated decompensated cardiac, hepatic, respiratory, or renal diseases.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07606794 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Supra-Iliac Anterior Quadratus Lumborum Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07606794 currently recruiting?
Yes, NCT07606794 is actively recruiting participants. Contact the research team at mselsharkawy@med.tanta.edu.eg for enrollment information.
Where is the NCT07606794 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07606794 clinical trial?
NCT07606794 is sponsored by Tanta University. The trial plans to enroll 50 participants.